NO2686520T3 - - Google Patents

Info

Publication number
NO2686520T3
NO2686520T3 NO12759983A NO12759983A NO2686520T3 NO 2686520 T3 NO2686520 T3 NO 2686520T3 NO 12759983 A NO12759983 A NO 12759983A NO 12759983 A NO12759983 A NO 12759983A NO 2686520 T3 NO2686520 T3 NO 2686520T3
Authority
NO
Norway
Application number
NO12759983A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2686520T3 publication Critical patent/NO2686520T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
NO12759983A 2011-06-06 2012-03-05 NO2686520T3 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06

Publications (1)

Publication Number Publication Date
NO2686520T3 true NO2686520T3 (zh) 2018-03-17

Family

ID=47262177

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12759983A NO2686520T3 (zh) 2011-06-06 2012-03-05

Country Status (24)

Country Link
US (6) US9145366B2 (zh)
EP (5) EP2718265B1 (zh)
JP (6) JP6290781B2 (zh)
KR (5) KR102000485B1 (zh)
CN (1) CN106518759B (zh)
AU (4) AU2012268426B2 (zh)
CA (2) CA3135440A1 (zh)
CY (4) CY1117177T1 (zh)
DK (4) DK3000808T3 (zh)
ES (4) ES2771232T3 (zh)
HK (3) HK1196616A1 (zh)
HR (4) HRP20211916T1 (zh)
HU (4) HUE057571T2 (zh)
IL (1) IL229775A (zh)
LT (3) LT3290404T (zh)
MX (2) MX337216B (zh)
NO (1) NO2686520T3 (zh)
PL (4) PL3683209T3 (zh)
PT (4) PT3290404T (zh)
RS (3) RS54517B1 (zh)
RU (2) RU2764667C2 (zh)
SI (4) SI3683209T1 (zh)
SM (1) SMT201600013B (zh)
WO (1) WO2012170377A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113838B2 (ja) * 2006-06-26 2013-01-09 アケビア セラピューティックス， インコーポレイテッド プロリルヒドロキシラーゼ阻害剤および使用方法
NO2686520T3 (zh) 2011-06-06 2018-03-17
MX2015017229A (es) * 2013-06-13 2016-04-19 Akebia Therapeutics Inc Composiciones y metodos para tratar anemia.
MX2016006271A (es) 2013-11-15 2017-05-04 Akebia Therapeutics Inc Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
US20180065933A1 (en) * 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
CN110088088B (zh) * 2016-12-13 2022-03-29 苏州科睿思制药有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
US10919843B2 (en) * 2017-03-29 2021-02-16 Emerald Health Pharmaceuticals Inc. Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
EP3790863A1 (en) * 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
WO2020108941A1 (en) 2018-11-28 2020-06-04 Sandoz Ag Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
CN113767089A (zh) * 2019-04-26 2021-12-07 株式会社钟化 伐度司他中间体的制造方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 一种羟基吡啶配体及其制备方法和催化应用
JPWO2021117767A1 (zh) * 2019-12-10 2021-06-17
CN115023288A (zh) 2020-01-24 2022-09-06 先技精工(日本)有限公司 光催化组件和包括该光催化组件的口罩
US20230286918A1 (en) * 2020-07-02 2023-09-14 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2023111990A1 (en) 2021-12-17 2023-06-22 Akebia Therapeutics, Inc. Selective phd1 inhibitor compounds, compositions, and methods of use

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (zh) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59401924D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
CA2253282A1 (en) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
TR200002740T2 (tr) 1998-03-23 2000-12-21 Aventis Pharmaceuticals Products Inc. Piperidinil ve N-Amidinopiperidinil türevleri
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CA2467689C (en) 2001-12-06 2013-10-01 Fibrogen, Inc. Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase
CA2486141A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7163951B2 (en) * 2002-08-29 2007-01-16 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
ATE452204T1 (de) 2002-10-16 2010-01-15 Isis Innovation Screening-methoden unter verwendung eines strukturmodells von fih
AU2003298611A1 (en) 2002-11-21 2004-06-18 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
DK1644336T3 (da) 2003-06-06 2011-05-09 Fibrogen Inc Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
ES2332798T3 (es) 2004-05-28 2010-02-12 Fibrogen, Inc. Ensayo de actividad de la prolil hidroxilasa de hif.
JP2008500951A (ja) 2004-05-31 2008-01-17 田辺三菱製薬株式会社 二環化合物
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CA2610956A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
EP1960363B1 (en) 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
CA2635370A1 (en) 2006-01-09 2007-07-09 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
JP5113838B2 (ja) 2006-06-26 2013-01-09 アケビア セラピューティックス， インコーポレイテッド プロリルヒドロキシラーゼ阻害剤および使用方法
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
AU2008241577B2 (en) 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
CA2685216C (en) 2007-05-04 2014-07-08 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US8268794B2 (en) 2007-08-06 2012-09-18 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CN101815718A (zh) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 吡啶衍生物及其用法
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009070644A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
NZ585701A (en) 2007-11-30 2012-09-28 Glaxosmithkline Llc Benzopyrazine derivatives as prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
PL2268618T3 (pl) * 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
US20090228298A1 (en) * 2008-03-04 2009-09-10 The General Electric Company System and method of morphology feature analysis of physiological data
CN102036558A (zh) * 2008-03-20 2011-04-27 森林实验室控股有限公司 作为硬脂酰-CoA去饱和酶抑制剂的新颖哌啶衍生物
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
BRPI0916233A2 (pt) 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais
CN102149703B (zh) 2008-09-15 2014-09-10 卡斯娜莱拉伊诺制药私人有限公司 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
CA2755132C (en) * 2009-03-31 2018-02-13 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes
DK2853265T3 (da) 2009-11-06 2017-11-06 Aerpio Therapeutics Inc Fremgangsmåder til at øge stabiliseringen af hypoxi-inducerbar faktor-1-alpha
US20120329836A1 (en) 2011-06-06 2012-12-27 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (zh) 2011-06-06 2018-03-17
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
KR102029951B1 (ko) 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
MX2015017229A (es) 2013-06-13 2016-04-19 Akebia Therapeutics Inc Composiciones y metodos para tratar anemia.
RU2016109125A (ru) 2013-08-16 2017-09-22 Огайо Стейт Инновейшн Фаундейшн Композиции и способы модуляции метилирования днк
MX2016006271A (es) 2013-11-15 2017-05-04 Akebia Therapeutics Inc Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
EP3096617A4 (en) 2014-01-23 2017-09-13 Akebia Therapeutics Inc. Compositions and methods for treating ocular diseases
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid

Also Published As

Publication number Publication date
CN106518759B (zh) 2019-07-30
SI2718265T1 (sl) 2016-03-31
AU2020204528A1 (en) 2020-07-30
KR102059366B1 (ko) 2019-12-26
JP2014522409A (ja) 2014-09-04
EP2718265A1 (en) 2014-04-16
ES2559850T3 (es) 2016-02-16
EP3000808B1 (en) 2017-09-27
AU2017202414B2 (en) 2018-07-19
PL3000808T3 (pl) 2018-03-30
JP2018111697A (ja) 2018-07-19
DK3000808T3 (da) 2017-11-27
EP3290404B1 (en) 2019-12-11
HK1216173A1 (zh) 2016-10-21
JP7284309B2 (ja) 2023-05-30
JP6510094B2 (ja) 2019-05-08
HK1252109A1 (zh) 2019-05-17
JP2022081597A (ja) 2022-05-31
CA2838194A1 (en) 2012-12-13
US20150361043A1 (en) 2015-12-17
EP3290404A1 (en) 2018-03-07
DK2718265T3 (en) 2016-01-25
RS59902B1 (sr) 2020-03-31
US9145366B2 (en) 2015-09-29
US20190375713A1 (en) 2019-12-12
RS56580B1 (sr) 2018-02-28
HK1196616A1 (zh) 2014-12-19
KR102032864B1 (ko) 2019-10-16
HRP20211916T1 (hr) 2022-03-18
ES2647602T3 (es) 2017-12-22
AU2020204528B2 (en) 2022-07-14
RU2764667C2 (ru) 2022-01-19
WO2012170377A1 (en) 2012-12-13
MX347709B (es) 2017-05-10
RU2602083C2 (ru) 2016-11-10
LT3683209T (lt) 2022-01-10
PT3683209T (pt) 2021-12-15
PT3290404T (pt) 2020-02-19
JP7039682B2 (ja) 2022-03-22
KR20190141805A (ko) 2019-12-24
KR102293016B1 (ko) 2021-08-26
PT2718265E (pt) 2016-02-15
MX2013014228A (es) 2014-03-26
HUE048044T2 (hu) 2020-05-28
JP2023103414A (ja) 2023-07-26
HRP20171740T1 (hr) 2018-03-09
EP3683209B1 (en) 2021-11-10
CY1117177T1 (el) 2017-04-05
US20230002323A1 (en) 2023-01-05
US11267785B2 (en) 2022-03-08
JP6816195B2 (ja) 2021-01-20
MX337216B (es) 2016-02-18
JP2021059573A (ja) 2021-04-15
IL229775A (en) 2016-06-30
ES2900572T3 (es) 2022-03-17
US20120309977A1 (en) 2012-12-06
AU2018250355A1 (en) 2018-11-08
EP3683209A1 (en) 2020-07-22
CN106518759A (zh) 2017-03-22
EP4026829A1 (en) 2022-07-13
DK3290404T3 (da) 2020-02-17
CA2838194C (en) 2022-01-11
HRP20151416T1 (hr) 2016-03-25
PL3290404T3 (pl) 2020-06-01
SI3000808T1 (en) 2018-02-28
KR20190032617A (ko) 2019-03-27
CY1119605T1 (el) 2018-04-04
JP2019123741A (ja) 2019-07-25
NZ618570A (en) 2015-07-31
JP6290781B2 (ja) 2018-03-07
PL3683209T3 (pl) 2022-02-21
HUE034975T2 (en) 2018-05-02
AU2012268426A1 (en) 2014-01-09
CY1124874T1 (el) 2022-11-25
LT3290404T (lt) 2020-02-25
US10738010B2 (en) 2020-08-11
HRP20200197T1 (hr) 2020-05-15
AU2012268426B2 (en) 2017-02-16
EP2718265B1 (en) 2015-12-16
RU2016139352A3 (zh) 2020-01-27
CA3135440A1 (en) 2012-12-13
HUE026096T2 (en) 2016-05-30
KR102000485B1 (ko) 2019-07-16
KR102171315B1 (ko) 2020-10-28
US20210122715A1 (en) 2021-04-29
CY1122639T1 (el) 2021-03-12
AU2017202414A1 (en) 2017-05-04
SI3290404T1 (sl) 2020-03-31
HUE057571T2 (hu) 2022-05-28
KR20190031593A (ko) 2019-03-26
RS54517B1 (en) 2016-06-30
AU2018250355B2 (en) 2020-04-09
SMT201600013B (it) 2016-02-25
PL2718265T3 (pl) 2016-04-29
LT3000808T (lt) 2018-01-25
US20170362178A1 (en) 2017-12-21
RU2013158640A (ru) 2015-07-20
DK3683209T3 (da) 2021-12-06
EP3000808A1 (en) 2016-03-30
SI3683209T1 (sl) 2022-03-31
KR20200121911A (ko) 2020-10-26
US9776969B2 (en) 2017-10-03
US10246416B2 (en) 2019-04-02
RU2016139352A (ru) 2018-12-13
KR20140037192A (ko) 2014-03-26
ES2771232T3 (es) 2020-07-06
CN103717575A (zh) 2014-04-09
EP2718265A4 (en) 2014-11-19
PT3000808T (pt) 2017-11-23

Similar Documents

Publication Publication Date Title
AP3853A (zh)
BR112013031251A2 (zh)
BR112013027245A2 (zh)
BR112013024383A2 (zh)
BR112013026905A2 (zh)
BR112013023185A2 (zh)
BR112013022995A2 (zh)
BR112013017670A2 (zh)
BR112013026744A2 (zh)
BR112013023927A2 (zh)
BR112013027830A2 (zh)
BR112013024365A2 (zh)
BR112013028733A2 (zh)
BR112013027121A2 (zh)
BR112013027452A2 (zh)
BR112013031556A2 (zh)
BR112013026790A2 (zh)
BR112013024588A2 (zh)
BR112013032377A2 (zh)
BR112013032380A2 (zh)
BR112013032366A2 (zh)
BR112013018949A2 (zh)
BR112013026895A2 (zh)
BR112013027761A2 (zh)
BR112013021637A2 (zh)